Development of a minor histocompatibility antigen vaccine regimen in the canine model of hematopoietic cell transplantation

Transplantation

Volumn 99, Issue 10, 2015, Pages 2083-2094

  Rosinski, Steven Lawrence ^a,b   Stone, Brad ^b   Graves, Scott S ^a,b   Fuller, Deborah H ^b   De Rosa, Stephen C ^a,b   Spies, Gregory A ^a   Mize, Gregory J ^a   Fuller, James T ^b   Storb, Rainer ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MINOR HISTOCOMPATIBILITY ANTIGEN; DNA; PEPTIDE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; CANINE MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DNA IMMUNIZATION; DONOR LYMPHOCYTE INFUSION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC CELL TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ADENOVIRIDAE; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANIMAL; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DOG; DONOR; GRAFT VERSUS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE; METABOLISM; PLASMID;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; DNA; DOGS; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; MINOR HISTOCOMPATIBILITY ANTIGENS; PEPTIDES; PLASMIDS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84943196620     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000744     Document Type: Article

References (56)

1. Goulmy E, Termijtelen A, Bradley BA, et al. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977;266:544.
2. Storb R, Rudolph RH, Kolb HJ, et al. Marrow grafts between DL-A-matched canine littermates. Transplantation. 1973;15:92.
3. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068.
4. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:832, 895.
5. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041.
6. Minor Histocompatibility Antigens: From the Laboratory to the Clinic. Georgetown, Texas, USA: Landes Bioscience; 2000.
7. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy (Review). Cancer J. 2004;10:1.
8. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94:1201.
9. Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 2007;92:72.
10. Meij P, Jedema I, van der Hoorn MA, et al. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica. 2012;97:1205.
11. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010;115:3869.
12. van Loenen MM, Hagedoorn RS, Kester MG, et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific Tcells. Cancer Res. 2009;69:2034.
13. Fontaine P, Roy-Proulx G, Knafo L, et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med. 2001;7:789.
14. Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood. 2011;118:5965.
15. Thomas ED. Nobel Lecture: Bone Marrow Transplantation? Past, Present and Future. In: Frängsmyr T, Linsten J, eds. Nobel Lectures, Physiology or Medicine 1981-1990. Singapore: World Scientific Publishing; 1993; http://www.nobelprize.org/nobel-prizes/medicine/laureates/1990/thomas-lecture.html-Date Accessed: enter today's date.
16. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048.
17. Lesnikova M, Nikitine A, Mason N, et al. Ex vivo expanded T regulatory (Treg) cells block conversion of mixed chimeras to complete donor chimerism. Blood (ASH Annual Meeting Abstracts). 2006;108:5168 (abstract).
18. + regulatory T cells (Treg) block alloreactive host anti-donor T cells in canine mixed hematopoietic chimeras. Blood (ASH Annual Meeting Abstracts). 2005;106:3101 (abstract).
19. Georges GE, Storb R, Thompson JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood. 2000;95:3262.
20. Weiden PL, Storb R, Tsoi M-S, et al. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J Immunol. 1976;116:1212.
21. Graves SS, Hogan WJ, Kuhr C, et al. Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism. Biol Blood Marrow Transplant. 2008;14:1201.
22. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-pre sentation of exogenous antigens (Review). Nat Immunol. 2004;5:678.
23. Venkataraman GM, Stroup P, Graves SS, et al. An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88∗01101 and DLA-88∗01201. Tissue Antigens. 2007;70:53.
24. Wagner JL, Burnett RC, DeRose SA, et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62:876.
25. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing (Brief Communication). Tissue Antigens. 1998;52:397.
26. Sorror ML, Leisenring W, Mielcarek M, et al. Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation. Transplantation. 2008;85:1023.
27. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58:701.
28. Ladiges WC, Storb R, Graham T, et al. Experimental techniques used to study the immune system of dogs and other large animals. In: Gay WI, Heavener JE, eds. Methods of Animal Experimentation. New York, NY: Academic Press; 1989:103.
29. Georges GE, Lesnikova M, Storb R, et al. Minor-histocompatibility antigen (miHA)-specific cytotoxic t-lymphocytes (CTL) generated with dendritic cells (DC) between dog leukocyte antigen (DLA)-indentical littermates. Blood. 2000;96(Part 1):770a.
30. Pertmer TM, Eisenbraun MD, McCabe D, et al. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 1995;13:1427.
31. Fuller DH, Murphey-Corb M, Clements J, et al. Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J Med Primatol. 1996;25:236.
32. Sandmaier BM, Storb R, Santos EB, et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood. 1996;87:3508.
33. Lupu M, Gooley T, Zellmer E, et al. Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation. J Vet Intern Med. 2008;22:74.
34. Wang Z, Storb R, Tapscott SJ, et al. Analyzing cellular immunity to AAV in a canine model using ELISPOT assay. In: Kalyuzhny AE, ed. Handbook of ELISPOT: Methods and Protocols. Clifton, NJ: Springer; 2012:65.
35. Eastwood D, Bird C, Dilger P, et al. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol. 2013;76:299.
36. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods. 1995;188:117.
37. Peiperl L, Morgan C, Moodie Z, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS ONE [Electronic Resource]. 2010;5:e13579.
38. Wick DA, Martin SD, Nelson BH, et al. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine. 2011;29:984.
39. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353.
40. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973.
41. Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2004;103:1961.
42. Mommaas B, Stegehuis-Kamp JA, van Halteren AG, et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood. 2005;105:1823.
43. Storb R, Epstein RB, Rudolph RH, et al. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol. 1970;105:627.
44. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411.
45. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer (Review). Nat Rev. 2008; Cancer. 8:108.
46. Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines (Review). Cancer J. 2011;17:359.
47. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens (Review). Curr Opin Immunol. 2005;17:202.
48. Spierings E, Goulmy E. Minor histocompatibility antigen typing by DNA sequencing for clinical practice in hematopoietic stem-cell transplantation. In: Christiansen FT, Tait BD, eds. Immunogenetics: Methods and Applications in Clinical Practice. New York: Springer Science + Business Media; 2012:509.
49. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005;438:803.
50. Suhrbier A. Multi-epitope DNA vaccines (Review). Immunol Cell Biol. 1997;75:402.
51. Graves SS, Mathes DW, Georges GE, et al. Long-term toleranceto kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model. Transplantation. 2012;94:562.
52. Taranova AG, Georges GE, Yunusov M, et al. Breaking tolerance in stable mixed chimeric dogs with low-dose TBI and donor or recipient lymphocyte infusion. Blood. 2003;102(Part 1):76a.
53. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5:508.
54. Murata S, Ladle BH, Kim PS, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol. 2006;176:974.
55. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways (Review). Immunol Rev. 2008;224:166.
56. Jager L, Hausl MA, Rauschhuber C, et al. A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc. 2009;4:547.